Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophreniaon February 10, 2025 at 7:15 am MAK Gojar 1 year ago Post Content Post Content Share this: Post TitleDateAugust 15, 2025In relation toSimilar postAlpha Star Holding IX concludes post-stabilization periodon February 20, 2025 at 9:04 amDateFebruary 20, 2025In relation toMarkets NewsJ.P. Morgan SE concludes CCF Holding’s post-stabilizationon February 20, 2025 at 9:02 amDateFebruary 20, 2025In relation toMarkets News
